From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer

International Journal of Cancer

Volumn 118, Issue 7, 2006, Pages 1750-1758

  Le Page, Cécile ^a   Ouellet, Véronique ^a   Madore, Jason ^a   Hudson, Thomas J ^b,c   Tonin, Patricia N ^b,c   Provencher, Diane M ^a,d   Mes Masson, Anne Marie ^a,d  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

CA125; FGF 2; IL 18; Ovarian cancer; Serum marker

Indexed keywords

CA 125 ANTIGEN; COMPLEMENTARY DNA; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 18; RNA; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM TUMOR; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SERUM;

CA-125 ANTIGEN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIUM; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-18; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; OVARY; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33644855779     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21521     Document Type: Article

References (43)

1. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88.
2. Serov SF, Scully R, Sobin LH. Histological typing of ovarian tumours, Vol. 9. Geneva: World Health Organization, 1973.
3. Chuaqui RF, Cole KA, Emmert-Buck MR, Merino MJ. Histopathology and molecular biology of ovarian epithelial tumors. Ann Diagn Pathol 1998;2:195-207.
4. Crispens MA. Borderline ovarian tumours: a review of the recent literature. Curr Opin Obstet Gynecol 2003;15(1):39-43.
5. Bast RC, Jr., Klug TL, Schaetzl E, Lavin P, Niloff JM, Greber TF, Zurawski VR, Jr., Knapp RC. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol 1984;149:553-9.
6. Modugno F. Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. Gynecol Oncol 2003;91(1): 15-31.
7. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC, Jr. Elevation of multiple serum markers in patients with stage 1 ovarian cancer. J Natl Cancer Inst 1993;85:1748-51.
8. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000;82:1535-8.
9. Le Page C, Provencher D, Maugard CM, Ouellet V, Mes-Masson AM. Signature of a silent killer: expression profiling in epithelial ovarian cancer. Expert Rev Mol Diagn 2004;4:157-67.
10. Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001;93:1458-64.
11. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671-9.
12. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004; 95:9-15.
13. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellstrom KE. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700.
14. Woolas RP, Conaway MR, Xu F, Jacobs IJ, Yu Y, Daly L, Davies AP, O'Briant K, Berchuck A, Soper JT, et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995;59: 111-6.
15. Kruk PA, Maines-Bandiera SL, Auersperg N. A simplified method to culture human ovarian surface epithelium. Lab Invest 1990;63:132-6.
16. Lounis H, Provencher D, Godbout C, Fink D, Milot MJ, Mes-Masson AM. Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. Exp Cell Res 1994;215:303-9.
17. Ouellet V, Provencher D, Maugard CM, Le Page C, Ren F, Lussier C, Novak J, Ge B, Hudson TJ, Tonin PN, Mes-Masson AM. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 2005;24:4672-87.
18. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
19. Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E, Lander ES, Golub TR. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci USA 1999;96:2907-12.
20. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-21.
21. Le Page C, Ouellet V, Madore J, Ren F, Hudson TJ, Tonin PN, Provencher D, Mes-Masson AM. Gene profiling in primary ovarian cultures highlights relevant markers of epithelial ovarian cancer. Br. J. Cancer, submitted.
22. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, Reed H, Ellenson LH, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002;62:4722-9.
23. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, Hampton GM. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 2001;98:1176-81.
24. Reddy P. Interleukin-18: recent advances. Curr Opin Hematol 2004; 11:405-10.
25. Wang ZY, Gaggero A, Rubartelli A, Rosso O, Miotti S, Mezzanzanica D, Canevari S, Ferrini S. Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: evidence for defective processing in tumor cells. Int J Cancer 2002;98:873-8.
26. Barak V, Elchalal U, Edelstein M, Kalickman I, Lewin A, Abramov Y. Interleukin-18 levels correlate with severe ovarian hyperstimulation syndrome. Fertil Steril 2004;82:415-20.
27. Gutman G, Soussan-Gutman L, Malcov M, Lessing JB, Amit A, Azem F. Interleukin-18 is high in the serum of IVF pregnancies with ovarian hyperstimulation syndrome. Am J Reprod Immunol 2004; 51:381-4.
28. Salgado R, Benoy I, Vermeulen P, van Dam P, Van Marck E, Dirix L. Circulating basic fibroblast growth factor is partly derived from the tumour in patients with colon, cervical and ovarian cancer. Angiogenesis 2004;7:29-32.
29. Dinarello CA. Interleukin-18. Methods. 1999;19:121-32.
30. Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. Evidence of IL-18 as a novel angiogenic mediator. J Immunol 2001; 167:1644-53.
31. Cao R, Wu HL, Veitonmaki N, Linden P, Farnebo J, Shi GY, Cao Y. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA 1999;96:5728-33.
32. Gaggero A, De Ambrosis A, Mezzanzanica D, Piazza T, Rubartelli A, Figini M, Canevari S, Ferrini S. A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and -4 processing. Oncogene 2004;23:7552-60.
33. Chen CH, Poucher SM, Lu J, Henry PD. Fibroblast growth factor 2: from laboratory evidence to clinical application. Curr Vasc Pharmacol 2004;2:33-43.
34. Sako A, Kitayama J, Yamaguchi H, Kaisaki S, Suzuki H, Fukatsu K, Fujii S, Nagawa H. Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: possible role of mesothelial cell on the development of peritoneal metastasis. J Surg Res 2003;115:113-20.
35. De Cecco L, Marchionni L, Gariboldi M, Reid JF, Lagonigro MS, Caramuta S, Ferrario C, Bussani E, Mezzanzanica D, Turatti F, Delia D, Daidone MG, et al. Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene 2004;23:8171-83.
36. Akahiro J, Konno R, Ito K, Okamura K, Yaegashi N. Impact of serum interleukin-18 level as a prognostic indicator in patients with epithelial ovarian carcinoma. Int J Clin Oncol. 2004;9:42-6.
37. Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De Pooler C, Martin M, Van Oosterom AT. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997;76:238-43.
38. Barton DP, Cai A, Wendt K, Young M, Gamero A, De Cesare S. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res 1997;3:1579-86.
39. Riedel F, Adam S, Feick P, Haas S, Gotte K, Hermann K. Expression of IL-18 in patients with head and neck squamous cell carcinoma. Int J Mol Med 2004; 13:267-72.
40. Alexandrakis MG, Passam FH, Sfiridaki K, Moschandrea J, Pappa C, Liapi D, Petreli E, Roussou P, Kyriakou DS. Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival. Leuk Res 2004;28:259-66.
41. Oku H, Tsuji Y, Kashiwamura SI, Adachi S, Kubota A, Okamura H, Koyama K. Role of IL-18 in pathogenesis of endometriosis. Hum Reprod 2004;19:709-14.
42. Airoldi I, Raffaghello L, Cocco C, Guglielmino R, Roncella S, Fedeli F, Gambini C, Pistoia V. Heterogeneous expression of interleukin-18 and its receptor in B-cell lymphoproliferative disorders deriving from naive, germinal center, and memory B lymphocytes. Clin Cancer Res 2004;10(1 Pt 1):144-54.
43. Zhang Z, Bast RC, Jr., Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64:5882-90.